Baker Brothers Advisors - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 238 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2021. The put-call ratio across all filers is 1.29 and the average weighting 0.1%.

Quarter-by-quarter ownership
Baker Brothers Advisors ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$48,717,401
+34.9%
1,366,547
+74.5%
0.28%
+34.4%
Q2 2023$36,122,512
+91.3%
783,059
+66.3%
0.21%
+102.9%
Q1 2023$18,886,057
-13.4%
470,9740.0%0.10%
-21.4%
Q4 2022$21,820,225
+11.9%
470,9740.0%0.13%
+2.3%
Q3 2022$19,503,000
-30.6%
470,9740.0%0.13%
-19.5%
Q2 2022$28,098,000
-12.9%
470,974
+6.0%
0.16%
-14.1%
Q1 2022$32,276,000
-13.6%
444,4440.0%0.18%
+1.6%
Q4 2021$37,373,000
-6.8%
444,4440.0%0.18%
+3.4%
Q3 2021$40,084,000
-5.4%
444,4440.0%0.18%
-5.4%
Q2 2021$42,378,000
-16.3%
444,4440.0%0.19%
-15.1%
Q1 2021$50,604,000
-17.7%
444,4440.0%0.22%
-5.6%
Q4 2020$61,524,000
+3861.6%
444,444
+1677.8%
0.23%
+1557.1%
Q2 2017$1,553,000
-54.2%
25,000
-50.0%
0.01%
-50.0%
Q1 2017$3,389,000
-3.6%
50,0000.0%0.03%
-17.6%
Q4 2016$3,516,000
-50.4%
50,000
-50.0%
0.03%
-46.9%
Q3 2016$7,094,000
+30.8%
100,000
-9.8%
0.06%
+12.3%
Q2 2016$5,424,000
-30.9%
110,894
-10.5%
0.06%
-31.3%
Q1 2016$7,844,000
-43.6%
123,8940.0%0.08%
-27.8%
Q4 2015$13,898,000
+16.5%
123,8940.0%0.12%
+4.5%
Q3 2015$11,932,000
-5.9%
123,8940.0%0.11%
-0.9%
Q2 2015$12,686,000
+37.2%
123,894
-16.8%
0.11%
+44.2%
Q1 2015$9,245,000
+40.5%
148,894
-0.7%
0.08%
+14.9%
Q4 2014$6,582,000
-22.5%
150,0000.0%0.07%
-37.4%
Q3 2014$8,490,000
+89.1%
150,000
+50.0%
0.11%
+94.5%
Q2 2014$4,489,000
-8.2%
100,0000.0%0.06%
-11.3%
Q1 2014$4,889,000100,0000.06%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q2 2021
NameSharesValueWeighting ↓
First Light Asset Management, LLC 441,159$39,788,0002.62%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 103,100$9,286,0002.24%
Rock Springs Capital Management LP 801,109$72,252,0001.52%
Avidity Partners Management LP 455,000$41,036,0000.91%
Motley Fool Asset Management LLC 134,357$12,118,0000.79%
FEDERATED HERMES, INC. 3,987,032$359,590,0000.68%
EMERALD ADVISERS, LLC 196,124$17,688,0000.64%
Ergoteles LLC 128,100$11,553,0000.42%
Tekla Capital Management LLC 140,726$12,692,0000.41%
Beck Bode, LLC 14,990$1,352,0000.38%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders